Peregrine Pharmaceuticals (NASDAQ:PPHM) Trading Outlook
PEREGRINE PHARMA closed up 0.040 at 1.160. Volume was 60% above average (neutral) and Bollinger Bands were 1% wider than normal.
Open High Low Close Volume___
1.160 1.200 1.140 1.160 1,760,655
Technical Outlook
Short Term: Neutral
Intermediate Term: Bullish
Long Term: Bearish
Moving Averages: 10-period 50-period 200-period
Close: 1.13 1.10 1.27
Volatility: 90 62 55
Volume: 1,140,957 1,048,939 1,169,136
Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.
Summary
PEREGRINE PHARMA is currently 8.9% below its 200-period moving average and is in an upward trend. Volatility is high as compared to the average volatility over the last 10 periods. Our volume indicators reflect volume flowing into and out of PPHM.O at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bullish on PPHM.O and have had this outlook for the last 8 periods.
Momentum Indicators
Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.
Stochastic Oscillator
One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 48.2758. This is not an overbought or oversold reading. The last signal was a sell 2 period(s) ago.
Relative Strength Index (RSI)
The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 56.87. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a buy 63 period(s) ago.
Commodity Channel Index (CCI)
The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is 104.This is an overbought reading. However, a signal isn’t generated until the indicator crosses below 100. The last signal was a sell 2 period(s) ago.
MACD
The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a buy 25 period(s) ago.
Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, 124I-PGN650 (PGN650), and its brain cancer therapy Cotara. Bavituximab is the Company’s therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company’s primary goal for the PS-targeting platform is to continue to advance bavituximab in its ongoing Phase III SUNRISE trial (Stimulating ImmUne RespoNse thRough BavItuximab in a Phase III Lung Cancer Study) for the treatment of second-line non-small cell lung cancer (NSCLC).
The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line NSCLC (in combination with carboplatin and pemetrexed), HER2-negative metastatic breast cancer (in combination with paclitaxel), liver cancer (in combination with sorafenib), rectal adenocarcinoma (in combination with capecitabine and radiation therapy) and advanced melanoma (in combination with ipilimumab). The Company is also evaluating PGN650 for the imaging of multiple solid tumor type. The Company also has a wholly owned biomanufacturing subsidiary, Avid Bioservices, Inc., which provides commercial and clinical manufacturing services for the Company and third-party clients.
Bavituximab for the Treatment of Solid Tumors
The Company’s investigator-sponsored bavituximab clinical trials for Second-Line NSCLC consist of the Phase IIb trial evaluating bavituximab in combination with docetaxel and Phase III SUNRISE trial. The Phase IIb trial was a randomized, double-blind, placebo-controlled trial evaluating two dose levels of bavituximab plus docetaxel (bavituximab-containing arms) versus placebo plus docetaxel (control arm) as second-line treatment in 121 patients with Stage IIIb/IV NSCLC. Patients were randomized to one of three treatment arms at clinical sites worldwide. All patients were randomized to receive up to six 21-day cycles of docetaxel (75 milligram (mg)/square meter (m2)). In addition, one arm was randomized to receive bavituximab (3 mg/kilogram) weekly, a second arm was randomized to receive bavituximab (1 mg/kg) weekly, and a third arm was randomized to receive placebo weekly until progression or toxicity. The trial was designed to evaluate overall response rate, the primary endpoint, measured in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and progression-free survival, duration of response, overall survival, and safety, were secondary endpoints. The Phase III SUNRISE trial is a randomized, double-blind, placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in approximately 600 patients at clinical sites worldwide. The trial is enrolling stage IIIb/IV non-squamous NSCLC patients who have progressed after standard front-line treatment. Patients are randomized into one of two treatment arms. One treatment arm receives docetaxel (75 mg/m2), up to six 21-day cycles, in combination with bavituximab (3mg/kg) weekly until progression or toxicity. The other treatment arm receives docetaxel (75 mg/m2), up to six 21-day cycles, in combination with placebo weekly until progression or toxicity. The primary endpoint of the trial is overall survival. This trial is currently enrolling patients.
The Company’s investigator-sponsored bavituximab clinical trial for Front-Line NSCLC consists of a Phase Ib trial designed to assess bavituximab with pemetrexed and carboplatin in up to 25 patients with locally advanced or metastatic NSCLC. Interim data conducted on a small number of patients demonstrated encouraging response rates with the combination of carboplatin, pemetrexed and bavituximab. Patient enrollment for the Phase Ib trial is complete. The Company’s investigator-sponsored bavituximab clinical trial for HER2-negative metastatic breast cancer (MBC) consists of a Phase I trial designed to assess bavituximab combined with paclitaxel in up to 14 patients with HER2-negative metastatic breast cancer. Interim data showed that from 13 evaluable patients, 85% achieved an objective tumor response, including 15% of patients achieving a complete response measured in accordance with RECIST criteria. Patient enrollment for the Phase I trial is complete.
The Company is conducting an investigator-sponsored Phase I/II trial designed to evaluate bavituximab combined with sorafenib in up to 48 patients with advanced liver cancer. Data from the trials showed that of the nine patients enrolled in the Phase I portion of the study, no dose-limiting toxicities or serious adverse events were observed and the trial is enrolling the Phase II part of the study. The Company is also conducting a Phase I investigator-sponsored trial designed to assess bavituximab in combination with capecitabine and radiation therapy in up to 18 patients with Stage II or III rectal adenocarcinoma. This trial continues to enroll and dose patients. In April 2014, the Company initiated an investigator-sponsored Phase Ib trial designed to assess bavituximab in combination with ipilimumab in up to 24 patients with advanced melanoma. This trial is open for enrollment.
PS-Targeting Molecular Imaging Program (PGN650)
The Company’s initial clinical candidate is PGN650, a first-in-class PS-targeting F(ab)2 fully human monoclonal antibody fragment joined to the positron emission tomography (PET) imaging radio-isotope iodine-124 that represents a potential new approach to imaging cancer. In preclinical studies, PGN650 accumulates in tumor vasculature and provides exceedingly clear in vivo tumor images. The Company’s PGN650 clinical trial evaluating PGN650 imaging in multiple solid tumor types was filed under an exploratory Investigational New Drug with the Food and Drug Administration. Patients receive an imaging dose followed by three PET images. This trial continues to enroll and dose patients.
The Company competes with Biothera, Merck & Co., Inc., AstraZeneca plc, Eli Lilly & Company, Roche and Bristol-Myers Squibb Company.
The post Peregrine Pharmaceuticals (NASDAQ:PPHM) Trading Outlook appeared first on Live Trading News.